Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine
Sponsor: Nordlandssykehuset HF
Summary
There are still no reliable biomarkers for migraine; the diagnosis is based on symptomatology, and the pathogenesis remains largely a mystery. However, the past decade has seen a shift from a trial-and-error treatment strategy to a more biologically driven approach using CGRP-targeted drugs (gepants) and monoclonal antibodies (mAbs). This study aims to profile levels of perivascular and hypothalamic neuropeptides, as well as microRNA (miRNA) and neurotrophins, in individuals with migraine. The study builds on a previous pilot investigation (Neuropeptides during migraine attacks, REK 808581).
Official title: Biological Profiling Subjects With Migraine
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2026-09-17
Completion Date
2027-12-31
Last Updated
2026-09-21
Healthy Volunteers
Not specified
Conditions
Interventions
Rimegepant 75 MG
Study subjects who during a 6-month period experience a migraine attack at work during daytime will contact study staff immediately and come for collection of blood, saliva and tear fluid samples. After that they will be treated with the oral dissolving CGRP receptor antagonist rimegepant tablet (Vydura®).
Locations (1)
Departement of Neurology, NLSH HF
Bodø, Norway